CYRX
Cryoport, Inc.
CYRX has lower modeled downside risk, despite its lower overall score.
RKLB
Rocket Lab USA, Inc.
RKLB has a slight edge over CYRX overall, supported by stronger fundamentals and stronger modeled upside.
CYRX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Under pressure | |
| Weak |
CYRX's revenue is currently healthy, but its profitability, cash flow and balance sheet are under pressure.
RKLB Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
RKLB's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
CYRX PE Valuation
CYRX has no meaningful PE right now: it lost money over the past year.
RKLB PE Valuation
RKLB has no meaningful PE right now: it lost money over the past year.
CYRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect CYRX's losses to shrink, with revenue growing.
RKLB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect RKLB's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
CYRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.89 | -176% |
| Q2 2026 | -$0.82 | -162% |
| Q1 2026 | $1.43 | +$3.77 |
| Q4 2025 | $1.40 | +$3.89 |
| Q3 2025 | $1.17 | +$4.56 |
| Q2 2025 | $1.33 | +$5.01 |
| Q1 2025 | -$2.34 | +$0.14 |
| Q4 2024 | -$2.49 | -$0.28 |
CYRX has the edge over RKLB on earnings, with more consistent year-over-year improvement.
RKLB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.36 | +$0.03 |
| Q2 2026 | -$0.27 | +$0.19 |
| Q1 2026 | -$0.32 | +$0.09 |
| Q4 2025 | -$0.37 | +$0.01 |
| Q3 2025 | -$0.39 | -$0.02 |
| Q2 2025 | -$0.46 | -$0.11 |
| Q1 2025 | -$0.41 | -$0.04 |
| Q4 2024 | -$0.38 | $0.00 |
RKLB is still losing money, but less than at its worst: $0.36 per share over the past year, against $0.46 at its worst in mid-2025.
CYRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $50.2M | +14% |
| Q2 2026 | $49M | +7.7% |
| Q1 2026 | $47.8M | +16% |
| Q4 2025 | $45.5M | -24% |
| Q3 2025 | $44.2M | -22% |
| Q2 2025 | $45.5M | -21% |
| Q1 2025 | $41M | -25% |
| Q4 2024 | $59.5M | +4% |
CYRX's revenue is recovering but still below its 2022 peak: $50M last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -18% | +4.9 points |
| Q2 2026 | -21% | +0.7 points |
| Q1 2026 | -20% | +3 points |
| Q4 2025 | -22% | +1.3 points |
| Q3 2025 | -22% | +6.5 points |
| Q2 2025 | -21% | +116 points |
| Q1 2025 | -23% | +16 points |
| Q4 2024 | -23% | +99 points |
CYRX has the edge over RKLB on profitability, with a higher operating margin.
RKLB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $267.8M | +73% |
| Q2 2026 | $234.1M | +62% |
| Q1 2026 | $200.3M | +63% |
| Q4 2025 | $179.7M | +36% |
| Q3 2025 | $155.1M | +48% |
| Q2 2025 | $144.5M | +36% |
| Q1 2025 | $122.6M | +32% |
| Q4 2024 | $132.4M | +121% |
RKLB has the edge over CYRX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -30% | +8.5 points |
| Q2 2026 | -25% | +17 points |
| Q1 2026 | -28% | +20 points |
| Q4 2025 | -28% | +11 points |
| Q3 2025 | -38% | +12 points |
| Q2 2025 | -41% | -0.5 points |
| Q1 2025 | -48% | -1.9 points |
| Q4 2024 | -39% | +41 points |
RKLB's operating margin was −30% last quarter, up 8.5 points from the same quarter a year ago.
CYRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$40K | +$1.2M |
| Q2 2026 | -$8M | +$3.7M |
| Q1 2026 | -$6.2M | +$1.3M |
| Q4 2025 | -$4.5M | +$6.2M |
| Q3 2025 | -$1.3M | +$2.5M |
| Q2 2025 | -$11.7M | +$119K |
| Q1 2025 | -$7.5M | -$239K |
| Q4 2024 | -$10.7M | -$1.6M |
CYRX has the edge over RKLB on cash flow, with more consistent year-over-year improvement.
RKLB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$23.9M | +$45.5M |
| Q2 2026 | -$110.1M | -$54.8M |
| Q1 2026 | -$77.4M | +$5.5M |
| Q4 2025 | -$114.2M | -$90.2M |
| Q3 2025 | -$69.4M | -$27.5M |
| Q2 2025 | -$55.3M | -$26.9M |
| Q1 2025 | -$82.9M | -$61.1M |
| Q4 2024 | -$23.9M | +$28.7M |
RKLB has burned cash in almost every quarter: −$326M over the past year, against −$232M the year before.
CYRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +211K shares |
| 1 year | +1.1% | +529K shares |
| 3 years | +3.6% | +1.7M shares |
| 5 years | +9.8% | +4.5M shares |
| Available history | +52% | +17.3M shares |
CYRX has the edge over RKLB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $2M |
| Q3 2025 | $3.7M |
| Q4 2022 | $4.6M |
| Q3 2022 | — |
| Q2 2022 | $25M |
| Q1 2022 | $8.3M |
RKLB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.6% | +22.6M shares |
| 1 year | +23% | +124M shares |
| 3 years | +35% | +168M shares |
| 5 years | +46% | +204M shares |
RKLB has 652M diluted shares, up 23% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CYRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2021 | 110.0x | High |
| Q3 2021 | 24.2x | High |
CYRX's net debt is more than 20 years of its operating earnings (EBITDA).
RKLB Net Leverage
RKLB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CYRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 71.7 | Overbought |
| Stochastic | 78.1 | Neutral |
CYRX's weekly RSI is 72 (overbought) and its Stochastic is 78 (neutral).
RKLB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.8 | Neutral |
| Stochastic | 27.6 | Neutral |
RKLB's weekly RSI is 47 (neutral) and its Stochastic is 28 (neutral).
CYRX PE vs Industrials Sector
| Metric | CYRX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 24x | — |
CYRX has no meaningful PE right now: it lost money over the past year.
RKLB PE vs Industrials Sector
RKLB has no meaningful PE right now: it lost money over the past year.
CYRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $17.9 | 12% above |
| 20 week MA | $16.7 | 20% above |
| 50 week MA | $13.1 | 53% above |
| 100 week MA | $10.4 | 94% above |
| 200 week MA | $12.4 | 63% above |
CYRX has the edge over RKLB on trend strength, trading above more of its moving averages.
RKLB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $61.4 | 4.3% above |
| 20 week MA | $68.1 | 5.9% below |
| 50 week MA | $77.6 | 17% below |
| 100 week MA | $56.5 | 13% above |
| 200 week MA | $31.4 | 104% above |
RKLB's trend is mixed: it's above three of its five weekly moving averages, and 104% above its 200-week average.
CYRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $16.2 | $45.8 | +182% |
| 2021 | $45.8 | $59.5 | +30% |
| 2022 | $59.5 | $16.4 | -72% |
| 2023 | $16.4 | $15.5 | -5.5% |
| 2024 | $15.5 | $7.80 | -50% |
| 2025 | $7.80 | $9.66 | +24% |
| 2026 YTD | $9.66 | $20.1 | +108% |
CYRX has the edge over RKLB on returns for 2026, with the stronger performance.
RKLB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.82 | $10.3 | +4.9% |
| 2021 | $10.3 | $12.0 | +17% |
| 2022 | $12.0 | $3.77 | -69% |
| 2023 | $3.77 | $5.53 | +47% |
| 2024 | $5.53 | $27.2 | +392% |
| 2025 | $27.2 | $70.7 | +160% |
| 2026 YTD | $70.7 | $64.1 | -9.3% |
RKLB's yearly returns have swung widely, from +392% in 2024 to −69% in 2022. It's down 9.3% so far in 2026.